| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Palmaturbine hydroxide does not have a well‑defined molecular target. It is structurally related to berberine and may act on similar pathways, including inhibition of pro‑inflammatory cytokines and modulation of oxidative stress. As a protoberberine alkaloid, it may intercalate with DNA or interact with various enzymes and receptors. Its bioactivity suggests potential in treating infections and possibly metabolic disorders.
|
|---|---|
| ln Vitro |
In vitro, Palmaturbine hydroxide exhibits antimicrobial, anti‑inflammatory, and cytotoxic properties. It is structurally related to berberine and may act on similar pathways, such as inhibiting pro‑inflammatory cytokines and modulating oxidative stress. Detailed in vitro activity data, such as IC50 values for specific targets, are not extensively documented in available sources.
|
| ln Vivo |
Specific in vivo activity data for Palmaturbine hydroxide are not extensively detailed in available sources. As a natural product alkaloid with reported antimicrobial, anti‑inflammatory, and cytotoxic properties, it may have potential for in vivo studies in infection and inflammation models.
|
| Enzyme Assay |
Non‑cellular assays for Palmaturbine hydroxide would depend on the specific target being studied. As a protoberberine alkaloid structurally related to berberine, typical assays include DNA intercalation studies using spectroscopic methods, enzyme inhibition assays, and binding studies with various receptors. The compound can be tested for its ability to inhibit pro‑inflammatory cytokine production or modulate oxidative stress in cell‑free systems.
|
| Cell Assay |
In vitro cellular assays for Palmaturbine hydroxide would involve treating cells with the compound to assess its antimicrobial, anti‑inflammatory, and cytotoxic effects. Cells would be treated with varying concentrations of the compound, and cell viability, cytokine production, and oxidative stress markers would be measured.
|
| Animal Protocol |
In vivo animal experiments for Palmaturbine hydroxide would typically be conducted in models of infection, inflammation, or metabolic disorders to evaluate its therapeutic potential. The compound would be administered via appropriate routes, and endpoints would include disease severity, inflammatory markers, and survival.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for Palmaturbine hydroxide are not extensively detailed in available sources. The compound has a molecular weight of 355.38 and a molecular formula of C20H21NO5. It is soluble in DMSO (83.33 mg/mL) and can be formulated for in vivo administration in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. It is a light brown to yellow solid powder and should be stored at 4°C, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for Palmaturbine hydroxide are not extensively detailed in available sources. As a natural product alkaloid, its safety profile would depend on the dose and route of administration. It is intended for research use only and not for human consumption. Standard safety precautions for handling alkaloids should be followed.
|
| References | |
| Additional Infomation |
Palmaturbine hydroxide is an isoquinoline alkaloid of the protoberberine subclass isolated from Tinospora sinensis. It has a molecular formula of C20H21NO5 and a molecular weight of 355.38. Structurally related to berberine, it may act on similar pathways, such as inhibiting pro‑inflammatory cytokines and modulating oxidative stress. It is used as a research compound for studying natural product bioactivity. It is not approved for clinical use.
|
| Molecular Formula |
C20H21NO5
|
|---|---|
| Molecular Weight |
355.38
|
| Related CAS # |
Palmaturbine;16176-68-4
|
| Appearance |
Light brown to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~83.33 mg/mL (~234.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8139 mL | 14.0694 mL | 28.1389 mL | |
| 5 mM | 0.5628 mL | 2.8139 mL | 5.6278 mL | |
| 10 mM | 0.2814 mL | 1.4069 mL | 2.8139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
